Serveur d'exploration Covid

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Alternative IP Mechanisms in Genomic Research

Identifieur interne : 000C92 ( Main/Exploration ); précédent : 000C91; suivant : 000C93

Alternative IP Mechanisms in Genomic Research

Auteurs : Cheryl Power ; Ed Levy ; Emily Marden ; Ben Warren

Source :

RBID : ISTEX:255956A39B64306BA111799D5F8C32E1F7EE943D

English descriptors

Abstract

This research is conducted by the Intellectual Property and Policy Research Group at the W. Maurice Young Centre for Applied Ethics at the University of British Columbia. It is part of the GE3LS (ethical, environmental, economic, legal and social issues related to genomics research) component of the Genome Canada Project "Dissecting Gene Expression Networks in Mammalian Organogenesis," MORGEN, which is located principally at the British Columbia Cancer Agency, Vancouver, British Columbia, Canada. The project is involved in upstream, basic genomic research. Part of this work includes the characterization of gene regulatory mechanisms governing organogenesis with a special focus on the heart, liver and pancreas. This paper serves as an introduction to both the MORGEN case study and the role of alternative mechanisms, such as open source. We discuss interim research results as they relate to our broader study of the relationship between open science, commercialization and technology transfer offices. The role of technology transfer offices (TTO) is central to our analysis and is viewed as a key factor in implementing Genome Canada policies and principles associated with IP and commercialization.

Url:
DOI: 10.2202/1941-6008.1052


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI wicri:istexFullTextTei="biblStruct">
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Alternative IP Mechanisms in Genomic Research</title>
<author>
<name sortKey="Power, Cheryl" sort="Power, Cheryl" uniqKey="Power C" first="Cheryl" last="Power">Cheryl Power</name>
</author>
<author>
<name sortKey="Levy, Ed" sort="Levy, Ed" uniqKey="Levy E" first="Ed" last="Levy">Ed Levy</name>
</author>
<author>
<name sortKey="Marden, Emily" sort="Marden, Emily" uniqKey="Marden E" first="Emily" last="Marden">Emily Marden</name>
</author>
<author>
<name sortKey="Warren, Ben" sort="Warren, Ben" uniqKey="Warren B" first="Ben" last="Warren">Ben Warren</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:255956A39B64306BA111799D5F8C32E1F7EE943D</idno>
<date when="2011" year="2011">2011</date>
<idno type="doi">10.2202/1941-6008.1052</idno>
<idno type="url">https://api.istex.fr/ark:/67375/QT4-L4HFB9TF-F/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000338</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000338</idno>
<idno type="wicri:Area/Istex/Curation">000318</idno>
<idno type="wicri:Area/Istex/Checkpoint">000099</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000099</idno>
<idno type="wicri:Area/Main/Merge">000C94</idno>
<idno type="wicri:Area/Main/Curation">000C92</idno>
<idno type="wicri:Area/Main/Exploration">000C92</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title level="a" type="main">Alternative IP Mechanisms in Genomic Research</title>
<author>
<name sortKey="Power, Cheryl" sort="Power, Cheryl" uniqKey="Power C" first="Cheryl" last="Power">Cheryl Power</name>
<affiliation>
<wicri:noCountry code="no comma">LLM</wicri:noCountry>
</affiliation>
</author>
<author>
<name sortKey="Levy, Ed" sort="Levy, Ed" uniqKey="Levy E" first="Ed" last="Levy">Ed Levy</name>
<affiliation>
<wicri:noCountry code="no comma">University of British Columbia</wicri:noCountry>
</affiliation>
</author>
<author>
<name sortKey="Marden, Emily" sort="Marden, Emily" uniqKey="Marden E" first="Emily" last="Marden">Emily Marden</name>
<affiliation>
<wicri:noCountry code="no comma">University of British Columbia</wicri:noCountry>
</affiliation>
</author>
<author>
<name sortKey="Warren, Ben" sort="Warren, Ben" uniqKey="Warren B" first="Ben" last="Warren">Ben Warren</name>
<affiliation>
<wicri:noCountry code="no comma">University of British Columbia</wicri:noCountry>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series>
<title level="j" type="main">Studies in Ethics, Law, and Technology</title>
<idno type="eISSN">1941-6008</idno>
<imprint>
<publisher>De Gruyter</publisher>
<date type="e-published">2008</date>
<biblScope unit="vol">2</biblScope>
<biblScope unit="issue">2</biblScope>
<biblScope unit="page-count">13</biblScope>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="Teeft" xml:lang="en">
<term>Academic technology transfer landscape</term>
<term>Alternative mechanisms</term>
<term>Available website</term>
<term>Biological targets</term>
<term>Biomedical research</term>
<term>British columbia</term>
<term>British columbia cancer agency</term>
<term>Broader access</term>
<term>Broader study</term>
<term>Carolina journal</term>
<term>Case study</term>
<term>Cell therapies</term>
<term>Commercialization</term>
<term>Commonwealth department</term>
<term>Complex situation</term>
<term>Creative commons</term>
<term>Discovery space</term>
<term>Efficient identification</term>
<term>Funding</term>
<term>Gene expression</term>
<term>Gene expression networks</term>
<term>Gene patenting</term>
<term>Genome</term>
<term>Genome canada</term>
<term>Genome canada data release policy</term>
<term>Genome canada policies</term>
<term>Genomic</term>
<term>Genomic research</term>
<term>Genomic research cheryl power</term>
<term>Genomics</term>
<term>Genomics research</term>
<term>Human gene patenting controversies</term>
<term>Independent voice</term>
<term>Intellectual property</term>
<term>Interim conclusions</term>
<term>Legal framework</term>
<term>Mammalian organogenesis project</term>
<term>Mouse atlas</term>
<term>National congress</term>
<term>National development</term>
<term>Nature biotechnology</term>
<term>Nematode caenorhabditis elegans</term>
<term>Online</term>
<term>Open science</term>
<term>Open source</term>
<term>Open source licenses</term>
<term>Open source philosophies</term>
<term>Organogenesis</term>
<term>Patent ownership</term>
<term>Patent pool</term>
<term>Patent pools</term>
<term>Patenting</term>
<term>Public domain</term>
<term>Research institutions</term>
<term>Research issues</term>
<term>Research results</term>
<term>Science training</term>
<term>Scientific research</term>
<term>Simon fraser university</term>
<term>Single gene deletions</term>
<term>Social issues</term>
<term>Special focus</term>
<term>Such approaches</term>
<term>Technology transfer</term>
<term>Technology transfer offices</term>
<term>University industry liaison office</term>
<term>Useful applications</term>
<term>Website</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">This research is conducted by the Intellectual Property and Policy Research Group at the W. Maurice Young Centre for Applied Ethics at the University of British Columbia. It is part of the GE3LS (ethical, environmental, economic, legal and social issues related to genomics research) component of the Genome Canada Project "Dissecting Gene Expression Networks in Mammalian Organogenesis," MORGEN, which is located principally at the British Columbia Cancer Agency, Vancouver, British Columbia, Canada. The project is involved in upstream, basic genomic research. Part of this work includes the characterization of gene regulatory mechanisms governing organogenesis with a special focus on the heart, liver and pancreas. This paper serves as an introduction to both the MORGEN case study and the role of alternative mechanisms, such as open source. We discuss interim research results as they relate to our broader study of the relationship between open science, commercialization and technology transfer offices. The role of technology transfer offices (TTO) is central to our analysis and is viewed as a key factor in implementing Genome Canada policies and principles associated with IP and commercialization.</div>
</front>
</TEI>
<affiliations>
<list></list>
<tree>
<noCountry>
<name sortKey="Levy, Ed" sort="Levy, Ed" uniqKey="Levy E" first="Ed" last="Levy">Ed Levy</name>
<name sortKey="Marden, Emily" sort="Marden, Emily" uniqKey="Marden E" first="Emily" last="Marden">Emily Marden</name>
<name sortKey="Power, Cheryl" sort="Power, Cheryl" uniqKey="Power C" first="Cheryl" last="Power">Cheryl Power</name>
<name sortKey="Warren, Ben" sort="Warren, Ben" uniqKey="Warren B" first="Ben" last="Warren">Ben Warren</name>
</noCountry>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/CovidV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C92 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000C92 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    CovidV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:255956A39B64306BA111799D5F8C32E1F7EE943D
   |texte=   Alternative IP Mechanisms in Genomic Research
}}

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Fri Mar 27 18:14:15 2020. Site generation: Sun Jan 31 15:15:08 2021